In a phase 1b/2a open-label study of long-acting HIV monoclonal antibodies, 16 of 17 virologically suppressed adults in the per-protocol phase 2a group remained suppressed at week 24 after stopping oral ART and receiving TMB-365 plus TMB-380 every 8 weeks. The study, registered as NCT05275998, also reported no serious or grade 3 or worse adverse events and no confirmed virological failures.

Why It Matters To Your Practice

• This is the kind of frontline HIV update NPs and PAs are uniquely positioned to operationalize: identifying stable, suppressed patients who may benefit from lower-treatment-burden maintenance strategies.

• For patients who struggle with daily pill fatigue, stigma, travel, or adherence friction, an every-8-week antibody regimen could eventually expand the menu beyond traditional oral ART.

• Your longitudinal relationships often surface the real-world barriers first, making your clinical judgment central, not secondary, when evaluating who might be a fit for future long-acting options.

Clinical Benefits

• In phase 2a, viral suppression at week 24 was 94% (16/17) in the per-protocol population and 80% (16/20) in the intention-to-treat population.

• Participants received 4800 mg of each antibody intravenously every 8 weeks for three doses over 24 weeks after discontinuing oral ART.

• No confirmed virological failures were reported, and pharmacokinetic targets were met at week 8 in the phase 1b 4800 mg group, supporting the dosing strategy studied.

Managing Risks

• This was a small, open-label early-phase study, so the results are promising but not practice-changing yet.

• The phase 2a cohort included 20 male participants, which limits generalizability across broader HIV populations.

• All treatment-emergent adverse events were mild or moderate, with no serious or grade 3 or worse events observed, but infusion logistics, follow-up reliability, and candidacy assessment would still matter in real-world use.

The Bottom Line

• TMB-365 plus TMB-380 every 8 weeks looks safe and active as maintenance therapy in virologically suppressed adults with HIV, and it merits further study.

• For NPs and PAs leading continuity care, this is a reminder that the future of HIV management will hinge not just on the drug, but on the clinician who knows the patient well enough to match innovation to real life.

• You are often the one translating trial signals into workable care plans, and this study reinforces how essential your role is in spotting the right patient, the right timing, and the right guardrails.

Reference: Safety, pharmacokinetics, and antiviral activity of a combination of TMB-365 and TMB-380 in people living with HIV suppressed with antiretroviral therapy in the USA: a phase 1b/2a, open-label, dose-escalation study.